clinical trial · NCT00648050
Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg
HealthyVerapamil Hydrochloride Extended-Release Capsules, 300 mgVerelan® PM Extended-Release Capsules, 300 mg
brief summary
The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following evening administration of a single, oral 300 mg (1 x 300 mg) dose administration under fasting conditions.
started
Mar 1, 2006
primary completion
Mar 1, 2006
completion
Mar 1, 2006
last updated
Apr 24, 2024
official title
Single-Dose Fasting Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg; Mylan) to Verelan® PM Extended-Release Capsules (300 mg; Schwarz) in Healthy Volunteers Dosed in the Evening
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol